Drug Database
KH

KH-741 (KH 741 / KH741)

✓ Approved

Chengdu Kanghong Pharmaceutical · Small Molecule · Small Molecule

What is KH-741?

KH-741 is a small molecule developed by Chengdu Kanghong Pharmaceutical. It is approved for therapeutic indications via unknown.

Drug Profile

Brand NamesKH 741, KH741
CompanyChengdu Kanghong Pharmaceutical
Drug ClassSmall Molecule
RouteUnknown
StatusApproved
Sources: ClinicalTrials.gov, Chengdu Kanghong Pharmaceutical

Therapeutic Indications

KH-741 is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Psychiatric disordersBipolar I disorder✓ Approved

Related Research Articles

PubMedInternational journal of biological macromolecules2026-11-09

PtoNAC086 promotes xylem development via activation of xylan glycosyltransferases in Populus tomentosa.

Fan Yawei Y, Cui Xincaiyu X, Zhang Mengyu M, Liu Han H et al.

In Populus, xylem development is organized by a four-layer NAC-MYB regulatory network. The NAC transcription factor (TF) family plays pivotal roles in secondary cell wall formation, yet the function of NAP homologs in woody plant xylem development remains unknown. Here, we showed that PtoNAC086, a third-layer member of this network and the poplar ortholog of AtNAP (NAC-LIKE, ACTIVATED BY AP3/PI; AT1G69490.1), acted as a transcriptional activator that promoted xylem development in Populus 741. Overexpression of PtoNAC086 significantly increased xylem thickness, cambial cell layers, vessel number, and lignin deposition. Integrating RNA-seq and DNA affinity purification sequencing (DAP-seq) analyses, we identified its direct target genes and validated that PtoNAC086 directly bound to and activated the promoters of two key xylan biosynthetic genes, PtoIRX10 (IRREGULAR XYLEM 10) (involved in xylan backbone elongation) and PtoGATL1 (GALACTURONOSYLTRANSFERASE-LIKE 1) (required for reducing-end tetrasaccharide synthesis), as well as the senescence-associated genes PtoERF017 (ETHYLENE-RESPONSIVE TRANSCRIPTION FACTOR 017) and PtoSAG113 (Senescence-Related Gene 113). By contrast, PtoNAC90, another third-layer NAC factor we previously characterized, promoted wood formation by activating a distinct set of genes. Together, these two third-layer TFs positively regulated xylem development through complementary downstream targets, highlighting the functional diversification of NAC family members in vascular development. Our findings uncovered a novel function of a NAP family TF in promoting secondary vascular development, expanding the regulatory repertoire of NAP homologs beyond leaf senescence in woody perennials.

PMID 43003209
Read full article →
PubMedAIDS (London, England)2026-11-09

Potential impact of the United States President's Emergency Plan for AIDS Relief funding cuts on the HIV and cervical cancer burden in Kenya.

Hathaway Christine L CL, Klein Sydney S, Guha Ashna A, Umutesi Grace G et al.

The withdrawal of the United States President's Emergency Plan for AIDS Relief (PEPFAR) funding has disrupted critical HIV services, including testing, antiretroviral therapy (ART), preexposure prophylaxis, voluntary medical male circumcision, and cervical cancer screening for women with HIV. We modelled the impact of PEPFAR funding scenarios on HIV and cervical cancer outcomes in Kenya. We used a dynamic compartmental model of HIV/human papilloma virus (HPV) for Kenya to evaluate PEPFAR funding scenarios beginning in 2025. Upper and lower bound scenarios simulated a 6-month service halt with partial ART interruption, followed by either full PEPFAR funding withdrawal or continued ART-only support. Both scenarios simulated the Ministry of Health recovery to 2025 funding levels by 2030. Outcomes were compared to scenarios without PEPFAR interruptions: the current status quo or uninterrupted PEPFAR funding meeting UNAIDS/WHO targets. Over the next 25 years, compared to the status quo, complete PEPFAR withdrawal is projected to cause 191-297 thousand more HIV cases and 132-206 thousand more HIV deaths. If PEPFAR maintains funding for ART, an additional 15-23 thousand HIV deaths and 32-44 thousand HIV cases are expected. Compared to achieving UNAIDS/WHO targets, complete withdrawal could result in an additional 808-915 thousand HIV cases and 667-741 thousand HIV deaths. Cervical cancer cases and deaths are projected to increase by 43-45 thousand and 19-20 thousand, respectively, if funding is completely withdrawn. Any interruptions in PEPFAR support could lead to thousands of HIV and cervical cancer cases and deaths in Kenya. Sustained funding is crucial to continue the progress made against HIV and cervical cancer.

PMID 43001759
Read full article →
PubMedAnimal nutrition (Zhongguo xu mu shou yi xue hui)2026-11-09

Effects of andrographolide on growth performance, serum indices, and multi-site microbial communities in weaned calves.

Zhou Xiaohan X, Zhao Chao C, Jia Ran R, He Zixian Z et al.

Weaning stress frequently induces systemic inflammation and oxidative stress in calves, thereby impairing growth performance and increasing susceptibility to gastrointestinal and respiratory diseases. Andrographolide (AG) is a natural active compound extracted from the medicinal plant Andrographis paniculata. It exhibits potent anti-inflammatory and antioxidant properties, but its impacts on calf physiological health and multi-site microbial ecosystems remain poorly understood. This study aimed to evaluate the effects of AG supplementation on growth performance, serum anti-inflammatory and antioxidant levels, and microbial communities across multiple sites (rumen, rectum, and nasal cavity) in weaned calves. Eighteen healthy Angus calves (age 90 ± 3 d, initial body weight 88.25 ± 4.98 kg) were randomly assigned to three groups (n = 6 per group): 0 mg/kg AG group (CON), 8 mg/kg AG group (L-AG), and 16 mg/kg AG group (H-AG). The trial lasted for 42 d. Results indicated that AG supplementation linearly increased calf average daily gain (ADG; P = 0.011); however, the L-AG group exhibited the most significant weight gain advantage during the latter phase (22-42 d) (P = 0.026). Serum analysis revealed that AG supplementation significantly enhanced calves' antioxidant (e.g., superoxide dismutase [SOD] and glutathione peroxidase [GSH-Px]) and anti-inflammatory (e.g., interleukin [IL]-4 and IL-10) capacities (P < 0.05), while markedly reducing pro-inflammatory factors (e.g., IL-1β, IL-2, and IL-6) and the oxidative stress marker (malondialdehyde) (P < 0.05); the H-AG group exhibited the most pronounced anti-inflammatory and antioxidant effects. Microbiome analysis revealed that AG treatment consistently remodeled microbial communities across all sites (P < 0.05). In the rumen, the L-AG group specifically enriched beneficial genera associated with volatile fatty acid (VFA) synthesis, including Pseudoscardovia, CAG-238, CAG-127, and CAG-793 (P adj < 0.05). In the nasal cavity, AG significantly reduced the abundance of multiple potential pathogenic microorganisms, including Pasteurella, Moraxella_C, Brevundimonas, and Exiguobacterium_A (P adj < 0.05). Furthermore, AG enhanced cross-site microbial interactions, with a numerical increase in cross-site edges (CON = 529, L-AG = 741, H-AG = 866). The AG treatments significantly altered the network topological structure (P < 0.05), suggesting a strengthening of the gut-lung axis. In summary, AG supplementation during calf weaning effectively suppressed inflammation and oxidative stress responses while improving growth performance and health status through multi-site microbial regulation. Based on the observed phenotypic and microbiome differences, L-AG appears to favor long-term growth benefits by optimizing rumen microbial communities, whereas H-AG maximizes short-term improvements through more potent anti-inflammatory and antioxidant effects.

PMID 43001315
Read full article →
PubMedbioRxiv : the preprint server for biology2026-11-08

Interdependent mode of RNA recognition by the interacting KH-domain proteins KhpA and KhpB.

Narayan Manasa M, Sharma Sahil S, Bischler Thorsten T, Lett Nay Won NW et al.

RNA-binding proteins (RBPs) are central regulators of gene expression. In bacteria, two KH domain-containing proteins, KhpA and KhpB, are increasingly recognized as globally-acting RBPs, including in pathogens that lack well-studied RBPs, such as Hfq and ProQ. While KhpA and KhpB interact with various RNAs in diverse bacteria, their crosstalk and molecular basis of RNA recognition remain poorly understood. Here, we explored the mutual dependence between KhpA and KhpB in the food-borne pathogen Campylobacter jejuni . We demonstrate KhpA and KhpB interact in vivo , and their individual global RNA recognition is largely dependent on the presence of the partner protein. Using RNA co-immunoprecipitation, we reveal that KhpA requires a conserved KH-domain motif for RNA binding, whereas KhpB relies on an atypical R3H domain. Moreover, mutating the RNA-binding domain of one protein compromises the RNA interactome of the other. Overall, we demonstrate an interdependent RNA-binding mode of KhpA and KhpB and anticipate that such KH-proteins have co-evolved to elicit joint RNA regulation in bacteria.

PMID 42999167
Read full article →
PubMedDevelopment (Cambridge, England)2026-11-06

The Bicaudal-C repression domain couples translational silencing to maternal embryonic patterning.

Kanzler Charlotte R CR, Johnson-Sheehan Emily T ET, Houston Douglas W DW, Aberle Olivia O et al.

The maternal period of embryonic development occurs before zygotic transcription is active and therefore relies heavily on post-transcriptional mechanisms such as regulated mRNA translation. Central to this regulation are RNA-binding proteins (RBPs), yet how individual RBPs orchestrate maternal gene regulation remains poorly understood. Bicaudal-C (Bicc1) is a conserved RBP and translational repressor that selects mRNAs through N-terminal KH domains and represses their translation through C-terminal activities whose mechanisms remain unclear. In the maternal Xenopus embryo, Bicc1 represses mRNAs encoding cell-fate regulators to establish the anterior/posterior axis. Here, we define the activities of the Bicc1 repression domain (Bicc1-RD). We show that the RD is sufficient for poly(A)-independent translational repression and mediates interactions with diverse RNA regulatory factors, including Bicc1 itself, the CCR4-NOT complex, and the translational regulators Lsm14, 4E-T, and Ddx6. Functional analyses reveal that RD activities are essential for maternal Bicc1-dependent patterning but dispensable for its zygotic role in left/right patterning, demonstrating mechanistically distinct Bicc1 repression strategies across developmental stages. These findings reveal how a modular RBP can coordinate stage-specific translational control during embryogenesis.

PMID 42990057
Read full article →
PubMedMedicine2026-11-06

Association between prior HBV vaccine responsiveness and booster-induced anti-SARS-CoV-2 spike antibody titers following the third BNT162b2 dose in Japanese healthcare workers: A prospective observational study.

Misawa Miwa M, Iwamoto Momoko M, Yamada Tomoyuki T, Kawanishi Fumiko F et al.

Inter-individual variability in vaccine-induced humoral responses has been reported even among generally healthy individuals. In our previous study, healthcare workers with poor hepatitis B virus (HBV) vaccine responsiveness were more likely to show a low anti-SARS-CoV-2 spike antibody response after the first BNT162b2 dose. This study examined whether such differences persisted after a third BNT162b2 dose. This was an extended follow-up study of a previously reported prospective observational cohort of Japanese healthcare workers. The primary outcome was the quantitative anti-SARS-CoV-2 spike antibody titer measured 12 weeks after the third BNT162b2 dose. Participants were classified as normal HBV vaccine responders, weak responders, or non-responders. Comparisons across HBV response groups were performed using the Kruskal-Wallis test and multivariable linear regression adjusted for age and sex. A low antibody-response analysis (<15 U/mL) after the first dose was evaluated as a secondary analysis. Among 741 participants with antibody measurements 12 weeks after the third dose, 486 were normal HBV vaccine responders, 229 were weak responders, and 26 were non-responders. The median anti-SARS-CoV-2 spike antibody titer was 891,900 U/mL. Titers did not differ significantly across HBV response groups in the unadjusted analysis (P = .3718) or after adjustment for age and sex (global P = .3971). Compared with normal responders, the adjusted geometric mean ratio was 0.94 (95% CI, 0.83-1.07) for weak responders and 0.83 (95% CI, 0.60-1.15) for non-responders. By contrast, after the first dose, HBV vaccine non-responders had an increased risk of a low antibody response (<15 U/mL) compared with normal responders (adjusted RR, 1.85; 95% CI, 1.10-3.13). Differences in early anti-SARS-CoV-2 spike antibody responses associated with prior HBV vaccine responsiveness were no longer statistically apparent 12 weeks after the third BNT162b2 dose. These findings suggest convergence of measured humoral antibody responses after booster vaccination, although they do not establish that the underlying biological mechanisms of vaccine hyporesponsiveness were eliminated.

PMID 42994824
Read full article →

+7998 more articles available with a free account

Sign up free to view all articles →

Ask about KH-741